Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Disease Management Pilot Project Estimated To Cost $300 Mil.

Executive Summary

A disease management program pilot project included in the House Medicare drug benefit bill (HR 4680) may have difficulty attracting private sector contractors, a Congressional Budget Office analysis of the bill indicates.

You may also be interested in...



House State-Based Senior Rx Plan Includes Funds For Pharmacy Services

State governments would be required to allocate a "reasonable percentage" of federal funding for senior drug assistance programs to cover the cost of pharmacy services under Rep. Bilirakis' (R-Fla.) HR 5151.

House State-Based Senior Rx Plan Includes Funds For Pharmacy Services

State governments would be required to allocate a "reasonable percentage" of federal funding for senior drug assistance programs to cover the cost of pharmacy services under Rep. Bilirakis' (R-Fla.) HR 5151.

Medicare Clinical Trial Policy May Improve Outcomes Data - HHS Panelist

Coverage of clinical trial costs under Medicare may lead to improved data for policy makers seeking to assess therapeutic outcomes in the elderly, Bruce Stuart, PhD, University of Maryland, suggested during the Aug. 8-9 HHS drug pricing conference in Washington, D.C.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel